Shionogi Lifts FY2025 Earnings and Projects Sharp Revenue Surge for FY2026

Shionogi & Co ( (JP:4507) ) just unveiled an announcement.

Shionogi reported fiscal 2025 revenue of ¥499.7 billion, up 14% year on year, driven by higher prescription drug sales, stronger overseas subsidiary and export performance, and a ¥33.9 billion increase in royalty income, mainly from its HIV franchise. Operating profit rose 6.5% to ¥166.7 billion despite higher SG&A and R&D costs linked to U.S. product launches, post-merger integration, and prioritized projects in infectious and QOL diseases, while profit attributable to owners climbed 20.4% to ¥205.2 billion.

Segment data show prescription drug revenue grew 25% to ¥123.5 billion, with solid contributions from products such as QUVIVIQ and SYMPROIC, even as acute respiratory virus treatments declined, and overseas revenue reached ¥65.0 billion on gains in the U.S. and Europe. For fiscal 2026, Shionogi forecasts revenue to surge to ¥700.0 billion and operating profit to ¥220.0 billion, anticipating strong growth in prescription drugs, particularly new launches like ZURZUVAE and expanded Torii Pharmaceutical-related products, as well as a further step-up in overseas sales and royalty income.

The most recent analyst rating on (JP:4507) stock is a Hold with a Yen3300.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.

More about Shionogi & Co

Shionogi & Co., Ltd. is a Japanese pharmaceutical company focused on prescription drugs, infectious disease treatments, and quality-of-life (QOL) therapies. The group, including overseas subsidiaries in the U.S., Europe, and China, also generates significant royalty income, notably from its HIV franchise, and engages in contract manufacturing and sales of OTC and quasi-drug products.

Average Trading Volume: 2,741,658

Technical Sentiment Signal: Buy

Current Market Cap: Yen2794.3B

For a thorough assessment of 4507 stock, go to TipRanks’ Stock Analysis page.